Clinical utility of gene signatures in breast cancer patients

Published 2017-12-06 14:17. Updated 2017-12-06 14:17

Nick Tobin, Arian Lundberg and colleagues have shown the broad clinical utility of the Recurrence Score and PAM50 breast cancer gene signatures in two papers published simultaneously in Clinical Cancer Research.

In paper 1, a collaboration with Dr. Thomas Hatschek and Prof. Jonas Bergh, Tobin et al. demonstrate the PAM50 gene expression signature can provide prognostic information when applied to the lymph node metastases of advanced breast cancer patients.

In paper 2, Lundberg and Tobin et al. demonstrate that the Recurrence Score and PAM50 signatures provide more prognostic information than clinically routine immunohistochemical markers in breast cancer patients.

Publications

PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. 
Tobin, NP, Lundberg, A, Lindström, LS, Harrell, JC, Foukakis, T, Carlsson, L, Einbeigi, Z, Linderholm, BK, Loman, N, Malmberg, M, Fernö, M, Czene, K, Perou, CM, Bergh, J, Hatschek, T.
Clin Cancer Res. 2017 Dec 1;23(23):7225-7231.

Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
Lundberg, A, Lindström, LS, Harrell, JC, Falato, C, Carlson, JW, Wright, PK, Foukakis, T, Perou, CM, Czene, K, Bergh, J, Tobin, NP.
Clin Cancer Res. 2017 Sep 29.

Breast cancerCancer genetics